Current and future developments in the use of temozolomide for the treatment of brain tumours

Lancet Oncology

Volumn 2, Issue 9, 2001, Pages 552-560

  Stupp, Roger ^a   Gander, Marc ^a   Leyvraz, Serge ^a   Newlands, Edward ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE; TEMOZOLOMIDE;

BRAIN TUMOR; DRUG RESISTANCE; GLIOMA; HUMAN; MULTIMODALITY CANCER THERAPY; REVIEW; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; GLIOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL;

EID: 0035469483     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(01)00489-2     Document Type: Review

References (73)

1. Stevens M.F., Newlands E.S. From triazines and triazenes to temozolomide. Eur J Cancer. 7:1993;1045-1047.
2. Newlands E.S., Stevens M.F., Wedge S.R., et al. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 23:1997;35-61.
3. Loo T. Triazenoimidazole derivatives. Sartorelli A., Johns D. Antineoplastic and immunosuppressive agents. 1975;553-554 Springer Verlag, Berlin.
4. Belanich M., Randall T., Pastor M.A., et al. Intracellular localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase. Cancer Chemother Pharmacol. 37:1996;547-555.
5. Friedman H., McLendon R., Kerby T., et al. DNA mismatch repair and O6-aklylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma. J Clin Oncol. 16:1998;3851-3857.
6. Stevens M.F., Hickman J.A., Stone R., et al. Antitumor imidazotetrazines: 1, synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one, a novel broad-spectrum antitumor agent. J Med Chem. 27:1984;196-201.
7. Gibson N.W., Hickman J.A., Erickson L.C. DNA cross-linking and cytotoxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d] -1,2,3,5-tetrazin-4(3H)-one. Cancer Res. 44:1984;1772-1775.
8. Stevens M.F., Hickman J.A., Langdon S.P., et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl- imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 47:1987;5846-5852.
9. Friedman H.S., Dolan M.E., Pegg A.E., et al. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res. 55:1995;2853-2857.
10. Plowman J., Waud W.R., Koutsoukos A.D., et al. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2- chloroethyl)-1-nitrosourea. Cancer Res. 54:1994;3793-3799.
11. Newlands E.S., Blackledge G.R.P., Slack J.A., et al. Phase I trial of temozolomide (CCRG 81045: M and B 39831: NSC 362856). Br J Cancer. 65:1992;287-291.
12. Marzolini C., Decosterd L.A., Shen F., et al. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. Cancer Chemother Pharmacol. 42:1998;433-440.
13. Brada M., Judson I., Beale P., et al. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer. 81:1999;1022-1030.
14. Tsang L.L., Farmer P.B., Gescher A., Slack J.A. Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity. Cancer Chemother Pharmacol. 26:1990;429-436.
15. Stupp R., Ostermann S., Leyvraz S., et al. Cerebrospinal fluid levels of temozolomide as a surrogate marker for brain penetration. Proc Am Soc Clin Oncol. 20:2001;59a. (abstr 232).
16. Clark A.S., Deans B., Stevens M.F., et al. Antitumor imidazotetrazines: synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide. J Med Chem. 38:1995;1493-1504.
17. Clark A.S., Stevens M.F., Sansom C.E., Schwalbe C.H. Anti-tumour imidazotetrazines, part XXI: mitozolomide and temozolomide: probes for the major groove of DNA. Anticancer Drug Des. 5:1990;63-68.
18. Denny B.J., Wheelhouse R.T., Stevens M.F., et al. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry. 33:1994;9045-9051.
19. Hickman M.J., Samson L.D. Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc Natl Acad Sci USA. 96:1999;10764-10769.
20. Karran P., Hampson R. Genomic instability and tolerance to alkylating agents. Cancer Surv. 28:1996;69-85.
21. Wedge S.R., Porteous J.K., May B.L., Newlands E.S. Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro. Br J Cancer. 73:1996;482-490.
22. 6-alkylguanine-DNA alkyltransferase attenuates triazene-induced cytotoxicity and tumor cell immunogenicity in murine L1210 leukemia. Cancer Res. 55:1995;6231-6236.
23. 6-alkylguanine-DNA alkyltransferase activity in human brain and brain tumors. Carcinogenesis. 5:1984;121-124.
24. Belanich M., Pastor M., Randall T., et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res. 56:1996;783-788.
25. Esteller M., Garcia-Foncillas J., Andion E., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 343:2000;1350-1354.
26. Liu L., Markowitz S., Gerson S.L. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res. 56:1996;5375-5379.
27. Middlemas D.S., Stewart C.F., Kirstein M.N., et al. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res. 6:2000;998-1007.
28. Wedge S.R., Porteous J.K., Newlands E.S. 3-Aminobenzamide and/or O(6)-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O(6)-alkylguanine-DNA alkyltransferase activity. Br J Cancer. 74:1996;1030-1036.
29. Delaney C.A., Wang L.Z., Kyle S., et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res. 6:2000;2860-2867.
30. Brock C.S., Newlands E.S., Wedge S.R., et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 58:1998;4363-4367.
31. Figueroa J., Tolcher A., Denis L., et al. Protracted cyclic administration of temozolomide is feasible; a phase I, pharmacokinetic and pharmacodynamic study. Proc Am Soc Clin Oncol. 19:2000;222a. (abstr 868).
32. Denis L., Tolcher A., Figueroa J., et al. Protracted daily administration of temozolomide is feasible: a phase I and pharmacokinetic-pharmacodynamic study. Proc Am Soc Clin Oncol. 19:2000;222a. (abstr 786).
33. Yung W.K., Prados M.D., Yaya-Tur R., et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse: Temodal Brain Tumor Group. J Clin Oncol. 17:1999;2762-2771.
34. Yung W.K., Albright R.E., Olson J., et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 83:2000;588-593.
35. Brada M., Hoang-Xuang K., Rampling R., et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol. 12:2001;259-266.
36. Macdonald D.R., Cascino T.L., Schold S.C., Cairncross J.G. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 8:1990;1277-1280.
37. Osoba D., Brada M., Yung W.K., Prados M.D. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer. 36:2000;1788-1795.
38. Osoba D., Brada M., Yung W., Prados M. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol. 18:2000;1481-1491.
39. Gilbert M., Olson J., Yung W., et al. Preradiation treatment of newly diagnosed anaplastic astrocytomas and glioblastoma multiforme using temozolomide. Neuro-Oncology. 2:2000;264. (abstr 77).
40. Wedge S.R., Porteous J.K., Glaser M.G., et al. In vitro# evaluation of temozolomide combined with X-irradiation. Anticancer Drugs. 8:1997;92-97.
41. van Rijn J., Heimans J.J., van den Berg J., van der Valk P., Slotman B.J. Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys. 47:2000;779-784.
42. Steel G.G., Peckham M.J. Exploitable mechansisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys. 5:1979;85-91.
43. Stupp R., Ostermann-Kraljevic S., Pica A., et al. Promising survival with concomitant and adjuvant temozolomide for newly diagnosed glioblastoma multiforme. Proc Am Soc Clin Oncol. 19:2000;163a. (abstr 632).
44. 6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer. 69:1994;452-456.
45. 6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Ann Oncol. 10:1999;831-838.
46. 6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol. 16:1998;3570-3575.
47. 6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 18:2000;3522-3528.
48. Schold S. Jr, Kuhn J., Chang S., et al. A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study. Neuro-Oncology. 2:2000;34-39.
49. Hammond L., Eckardt J., Kuhn J., et al. A phase I and pharmacokinetic trial of 2 sequences of BCNU and temozolomide in patients with advanced solid tumors. Neuro-Oncology. 2:2000;267. (abstr 90).
50. Friedman H.S., Petros W.P., Friedman A.H., et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 17:1999;1516-1525.
51. Reid J., Buckner J., Schaaf L., et al. Anticonvulsants alter the pharmacokinetics of irinotecan (CPT-11) in patients with recurrent glioma. Proc Am Soc Clin Oncol. 19:2000;160a. (abstr 620).
52. Cloughesy T., Filka E., Friedman H., et al. A phase I (intrapatient dose escalation) open-label study of irinotecan (CPT-11) in patients with recurrent or progressive malignant glioma. Proc Am Soc Clin Oncol. 19:2000;161a. (abstr 624).
53. 6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res. 6:2000;4110-4118.
54. Dichter M.A., Brodie M.J. New antiepileptic drugs. N Engl J Med. 334:1996;1583-1590.
55. Cairncross G., Macdonald D., Ludwin S., et al. Chemotherapy for anaplastic oligodendroglioma: National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 12:1994;2013-2021.
56. van den Bent M.J., Kros J.M., Heimans J.J., et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy: Dutch Neuro-oncology Group. Neurology. 51:1998;1140-1145.
57. Cairncross J.G., Ueki K., Zlatescu M.C., et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 90:1998;1473-1479.
58. Paleologos N.A., Macdonald D.R., Vick N.A., Cairncross J.G. Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology. 53:1999;1141-1143.
59. Chinot O. Jr, Honore S., Barrie M. Jr, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol. 19:2001;2449-2455.
60. Shaw E. Looking through the retrospectoscope in the era of evidence-based medicine. J Clin Oncol. 15:1997;1289-1290.
61. Cairncross J.G. Understanding low-grade glioma: a decade of progress. Neurology. 54:2000;1402-1403.
62. Karim A., Cornu P., Bleehen N., et al. Immediate postoperative radiotherapy in low grade glioma improves progression free survival, but not overall survival: preliminary results on an EORTC/MNRC randomized phase III study. Proc Am Soc Clin Oncol. 17:1998;400a. (abstr 1544).
63. Leighton C., Fisher B., Bauman G., et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol. 15:1997;1294-1301.
64. Olson J.D., Riedel E., DeAngelis L.M. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology. 54:2000;1442-1448.
65. Viviers L., Brada M., Hines F., et al. A phase II trial of primary chemotherapy with temozolomide in patients with low-grade cerebral gliomas. Proc Am Soc Clin Oncol. 19:2000;167a. (abstr 648).
66. Friedman A., Cokgor I., Edwards S., et al. Phase II treatment of anaplastic oligodendroglioma and low grade glioma with temozolomide. Proc Am Soc Clin Oncol. 19:2000;169a. (abstr 654).
67. Perry J.R., Brown M.T., Gockerman J.P. Acute leukemia following treatment of malignant glioma. J Neuro-Oncol. 40:1998;39-46.
68. Pedersen-Bjergaard J. Long-term complications of cancer chemotherapy. J Clin Oncol. 13:1995;1534-1536.
69. Christodoulou C., Bafaloukos D., Kosmidis P., et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol. 12:2001;249-254.
70. Reni M., Ferreri A.J., Landoni C., Villa E. Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. (letter). J Natl Cancer Inst. 92:2000;575-576.
71. Abrey L., Olson J., Boutros D., et al. A phase II study of temozolomide for recurrent brain metastases. Proc Am Soc Clin Oncol. 19:2000;166a. (abstr 643).
72. Antonadou D., Paraskevaides M., Coliarakis N., et al. Temozolomide enhances radiation treatment efficacy in brain metastases: a randomized phase II study. Neuro-Oncology. 2:2000;247. (abstr 6).
73. Gilbert M.R. Neuro-oncology clinical trials: promise and pitfalls. Ann Oncol. 12:2001;149-150.